Why the study?
What is the safety of NSAIDs and selective COX-2 inhibitors in patients with underlying atherosclerotic coronary disease?
What is the safety of NSAIDs and selective COX-2 inhibitors in patients with underlying atherosclerotic coronary disease?
NSAIDs and COX-2 inhibitors should be avoided or used at the lowest effective dose for the shortest duration in patients with atherosclerotic coronary disease.
Supports limiting NSAIDs in atherosclerotic CAD; leaves open need for randomized confirmation of risks.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most common classes of medication used worldwide, and as the ageing population increases, the prevalence of painful arthritic conditions parallels this, resulting in the increased use of NSAIDs. Selective and nonselective cyclo-oxygenase inhibitors should be avoided, or at best used for short periods at the lowest possible effective dose, in patients with underlying artherosclerotic coronary disease.
No takes yet. Share an insight, caveat, or question.
Tarr et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: